Secondary Schizophrenia (169 page)

conclusions,
297–
8

reduction in,
6, 6f
,
6

hard signs, in neurologic exam,

diagnostic categories of SZ,
289

reduction in adult with VCFS,
315

47–
8

DISC 1 illustrative example,
292–
5,

reduction in schizophrenia,
312

Harris, D.,
130–
1

295f
,
296

Green, A. I.,
135

cytogenetics, linkage, and

Harrison, G.,
188

association,
292–
4

Griffiths, T. D.,
48

Hatatoni, N.,
382

endophenotypes,
294–
6

growth hormone,
328

mRNA expression studies,
296

Heath, R. G.,
82–
3

Gupta, R.,
264–
5

protein expression studies,
296

hebephrenia,
289

protein interactors,
296

Gur, R. E.,
64–
5

heel-shin test,
50

future research,
297–
8

Gureje, O.,
187,
193

analytic,
297–
8

hematopoetic stem cell

clinical,
297

Gustafson, Y.,
206

transplantation,
244

laboratory,
297

gustatory hallucinations. See

hemianopia,
200,
232

population characteristics,
297

secondary olfactory and

replication,
298

gustatory hallucinations

hemiparesis,
48–
9,
51,
53,
85,
232

genetic complexity of SZ,
288

Hendron, R. L.,
382

implications for clinical practice,

habenula,
135

296

Hennah, W.,
293–
4

linkage studies,
292,
293f
,
Hafner, H.,
136

Henquet, C.,
171–
2,
173

309

Hakim, S.,
257

hepatolenticular degeneration. See

molecular diagnosis,
297

Wilson’s Disease

molecular genetics,
290

Hallucination Persisting Perception

molecular treatment,
297

Disorder (HPPD),
148

hereditar
y ataxias. See Friedrich’s

statistical genetics,
290–
2

hallucinations

Ataxia

association analysis,
291–
2

Alzheimer’s Disease (AD),
26–
7,

Hermann, B. P.,
90

linkage analysis,
290–
1

205,
207t

herpes simplex virus,
281–
2

genetics,
350

defining,
21

lesion-based,
24,
26f

Heschl’s gyrus,
30,
31

genomewide association studies

peduncular hallucinosis,
198

(GWA),
297–
8

HEX-A,
216

pharmacologically induced,
24–
5

genomewide scan (GWS),
291–
2

post-stroke psychosis,
198

HEX-B,
216

prevalence in community,
21–
2

Gershon, S.,
127,
131

hippocampus

prevalence in organic disorders,

cognitive processing role of,
5

Gibbs, F. A.,
82,
87

22–
3

maldevelopment of,
283

prevalence in psychiatric disorders,

glial fibrillary acidic protein (GFAP),

volume reduction in,
6

22
See also Charles Bonnet

249

Syndrome; hallucinations;

histamine H1 receptors,
67

Glithero, E.,
192

secondary auditory

histamine H2 receptor,
182

globoid cell leukodystrophy. See

hallucinations; seco
ndary

histone deacetylase inhibitor,
335

Krabbe’s Disease

olfactory and gustatory

hallucinations; secondary

Hodkinson, H. M.,
180

glutamate,
95

tactile hallucinations;

hodology,
61–
2,
374

glutamine,
106

secondary visual

hallucinations; secondary

Hoffler, J.,
382

Glutamate-N-methyl-D-Aspartic acid

visual hallucinations (VH)

(NMDA),
114

Hollister, H.,
266

hallucinosis

glycoproteinoses,
214–
15, 215t

Homayoun, H.,
150–
1

organic,
198

GM2-gangliosidosis type-1, Tay Sachs

peduncular,
26,
198

Hopkins, M. W.,
207

Disease (TSD),
216,
222

in post-stroke psychosis,
198

Horwood, J.,
172

ictal psychosis,
30,
81–
3

International HapMap,
290,
297

and cannabis use,
173

partial complex status,
81–
2

in vivo neuroimaging,
6,
7–
8

treatment,
396

petit mal status,
82

Human Genome Project,
290

seizures,
82–
3

simple partial status,
82

Jablensky, A.,
174

human immunodeficiency virus

Jacob, G.,
204

(HIV),
398

idebenone,
233,
234

imaginary friend,
24

Jacobs, P. A.,
292–
3

Huntington’s Disease (HD)

age of onset,
348

immunocytochemistry,
96

Janakiramaiah, N.,
382

antipsychotics for,
398–
9

impaired gag reflex,
49

Jeste, D. V.,
205,
206,
208

basal ganglia role in,
359

diagnosis,
350,
351t

impersistence test,
50,
349

Johns, L.,
22

presymptomatic,
350

Inagaki, T.,
233–
4

Johnstone, E.,
23

genetics role in,
350

infantile myoclonic epilepsy,
230

Jones, D. K.,
201

longitudinal course,
349–
50

other trinucleotide repeat disorders,

infections and schizophrenia

352t
,
353–
4

conclusions,
284

Kaido, M.,
235

polyglutamine (polyQ) repeat

early work on in utero infection,

Kaiser Permanente Medicare Care

disorders,
353

279

Plan (KPMCP),
280–
1

spinocerebellar ataxias,
353–
4

ecologic studies,
279–
80

overview of,
348

future research,
283

Kallman, F. J.,
288

and schizophrenia-like psychosis,

implications for clinical practice,

Kanemoto, K.,
84

350–
3

283

Kanner, A. M.,
83,
84

epidemiological association,

influenza,
279–
80

350–
2

serologic studies,
280t
,
280–
3

Kasanin, J.,
289

genetics,
352

cytokines,
282–
3

Kayser-Fleischer rings (KFRs),

neuropsychology,
353

herpes simplex virus,
281–
2

338

pathology,
352–
3

infection and schizophrenia in

treatment,
353

adults,
283

Kearns-Sayre Syndrome (KSS),

signs and symptoms,
348–
50

influenza,
280–
1

232

cognitive,
349

maternal genital/reproductive

Kendrick, J. F.,
82

neurological,
349

infections,
282

Kennard, M.,
48

psychiatric,
349

rubella,
282

Westphal variant,
349

toxoplasmosis,
281

Keschner, M.,
264

translational approaches,
283–
4

hyperactive deep tendon reflexes,
48

ketamine,
145–
7

influenza,
279–
81

illicit use,
145

hyperacusis,
28

Ingvar, D.,
60–
1

phycosis and,
87,
145–
6

hyperdopaminergic model of

studies on,
146–
7

schizophrenia,
7

inhibitory postsynaptic potential

symptoms,
145–
7

(IPSP),
84

hyperkinetic motor findings, in

Kety, S.,
60

schizophrenia,
51

Innui, K.,
382

kindling

hyperphagia,
328,
329

insertion/deletion variants (In/Dels),

electrical,
93,
105,
106

290,
297

hyperthermia,
149,
283

limbic,
93,
105–
6

insomnia,
412–
13

pharmaceutical,
93,
105–
6

hypnagogic visual hallucination,
23–
4,

28

intercranial pressure (ICP),
267

Kobari, M.,
358

hypnopompic visual hallucination,

intermittent explosive disorder,
397

Konig, P.,
360–
1

23–
4,
28

International Classification of

Krabbe’s Disease,
248

hypofrontality,
61f
,
61,
62f

Diseases (ICD),
289,
380–
1,

Kraepelin, E.,
49,
144–
5,
204,
288,
289,

382

hypogonadism,
243,
328

380–
1

ICD-9-CM,
274–
5

hypothalamic dysfunction,
328

ICD-10

Krishnamoorthy, E. S.,
105

delirium,
179

hypotonia,
50,
349